CareDx, Inc. (NASDAQ:CDNA - Get Free Report)'s stock price passed above its 50 day moving average during trading on Monday following insider buying activity. The stock has a 50 day moving average of $17.54 and traded as high as $19.23. CareDx shares last traded at $19.07, with a volume of 777,225 shares traded.
Wall Street Analysts Forecast Growth
Several research firms have commented on CDNA. HC Wainwright reiterated a "neutral" rating and issued a $25.00 target price on shares of CareDx in a research report on Monday, May 5th. Stephens reiterated an "overweight" rating and issued a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. The Goldman Sachs Group dropped their target price on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, Wall Street Zen downgraded CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $30.33.
Check Out Our Latest Stock Analysis on CDNA
CareDx Price Performance
The company has a market capitalization of $1.06 billion, a P/E ratio of 16.55 and a beta of 2.18. The stock has a 50-day moving average price of $17.57 and a 200-day moving average price of $20.11.
CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. CareDx had a return on equity of 21.16% and a net margin of 19.79%. The company had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same period last year, the company earned ($0.03) earnings per share. The firm's revenue was up 17.6% compared to the same quarter last year. Sell-side analysts anticipate that CareDx, Inc. will post -0.9 EPS for the current fiscal year.
Hedge Funds Weigh In On CareDx
A number of hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its position in shares of CareDx by 3.4% during the first quarter. Principal Financial Group Inc. now owns 19,624 shares of the company's stock worth $348,000 after acquiring an additional 640 shares during the last quarter. Sei Investments Co. raised its position in shares of CareDx by 1.7% during the first quarter. Sei Investments Co. now owns 47,921 shares of the company's stock worth $851,000 after acquiring an additional 816 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its position in shares of CareDx by 3.9% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company's stock worth $425,000 after acquiring an additional 900 shares during the last quarter. Thompson Davis & CO. Inc. raised its position in shares of CareDx by 6.3% during the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock worth $344,000 after acquiring an additional 950 shares during the last quarter. Finally, Hsbc Holdings PLC increased its holdings in CareDx by 6.9% in the fourth quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock worth $365,000 after purchasing an additional 1,109 shares in the last quarter.
CareDx Company Profile
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Further Reading
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
